John Pinching from PharmaTimes - Journalist Profile

	Profile	Recent Articles on Subject
1	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Genome editing offers hope for genetic hearing loss - 28 days ago Amivantamab plus lazertinib shows survival benefit in lung cancer - 28 days ago Linda Härmark - 29 days ago Nouscom reveals promising results for lynch syndrome immunotherapy - 29 days ago Seth Benson - 30 days ago Kieron Hall - 30 days ago SECuRE trial pre-chemo participants experience PSA level drops - about 2 months ago Rotherham NHS Foundation Trust enhances patient engagement - about 2 months ago Bas Vorsteveld - about 2 months ago Centauri therapeutics selects first ABX-01 clinical candidate - about 2 months ago Professor Dr Uli Brödl - about 2 months ago Blood cancer patients face treatment access disparity - about 2 months ago Datapharm collaborates with VIDAL to improve medicines information access in France - about 2 months ago Brainomix partners with Medtronic to enhance stroke care - about 2 months ago Microbiotica unveils new data on MB097 at AACR IO meeting - about 2 months ago Mitazalimab shows promising survival rates in cancer study - about 2 months ago Cambridge scientists develop ‘super test’ for prostate cancer - 2 months ago Bath researchers awarded Wellcome grant for psychotic disorder study - 2 months ago Andembry treatment approved across Europe - 2 months ago Illuccix therapy gets approval in the UK - 2 months ago Amlenetug receives FDA Fast Track Designation - 2 months ago Bimekizumab shows long-term efficacy in hidradenitis suppurativa - 2 months ago Libtayo available in Scotland for cervical cancer patients - 2 months ago Lynparza approved in Scotland for BRCA-mutated breast cancer patients - 2 months ago Capgemini unveils AI breakthrough to boost bioeconomy - 2 months ago Hemgenix shows efficacy among haemophilia B patients - 2 months ago Qureight and Avalyn launch strategic partnership in pulmonary fibrosis - 3 months ago FDA grants Orphan Drug Designation to Ariceum cancer therapy - 3 months ago Rippon Ubhi - 3 months ago Novartis secures MHRA authorisation for ribociclib - 3 months ago Grifols collaborates with startup FcR Therapeutics to develop autoimmune therapies - 3 months ago Aplagon secures EUR 7 million for APAC phase 2a trials - 3 months ago CHMP recommends SC Rybrevant for EGFR-mutated NSCLC patients - 3 months ago Biofidelity and CellCarta partner to deploy Aspyre Lung in global clinical trials - 3 months ago Actinogen boosts trial with Cambridge Cognition’s digital suite - 3 months ago Owlstone Medical announces $27 million USD first close in Series E financing round - 3 months ago Oxford Drug Design achieves in vivo validation for novel cancer treatment - 3 months ago Pheno Therapeutics granted trial authorisation for MS candidate - 3 months ago Grifols pioneers high-tech analysis of plasma bank to detect Parkinson’s disease - 3 months ago AI set to revolutionise pharmaceutical R&D says GlobalData - 3 months ago Gilead and LEO Pharma partner to develop oral STAT6 program - 3 months ago Cambridge Cognition highlights positive Cantab results - 4 months ago Angelini Ventures co-leads Series A financing in Neumirna Therapeutics - 4 months ago Novartis gene therapy set to enhance SMA treatment - 4 months ago Merck unveils new cyber-physical trust platform at CES 2025 - 4 months ago New prostate cancer test cuts biopsies by 50% in US - 4 months ago Amgen’s lung cancer treatment gets conditional approval - 4 months ago NHS Confederation welcomes social care commission announcement - 4 months ago FDA approves Sequana Medical’s Alfapump for ascites treatment - 4 months ago EC approves Rybrevant with Lazcluze for advanced lung cancer - 4 months ago
2	Urte Jakimaviciute PharmaTimes	AI set to revolutionise pharmaceutical R&D says GlobalData - 3 months ago
3	Christie Wong PharmaTimes	Novartis gene therapy set to enhance SMA treatment - 4 months ago